The frequency of CDH1 loss in sporadic and familial DGC, LCIS, and LBC suggests that targeting E-cadherin-deficiency in these cancers may provide an effective method for the chemoprevention of HDGC and new treatments for the sporadic disease. The gene discussed is CDH1; the disease is lobular breast carcinoma in situ.